However, increased levels of CCN2 have been described in experimental and human cardiovascular diseases, including heart failure, pulmonary hypertension, restenosis, atherosclerosis and aortic aneurysms [7,9], suggesting CCN2 as a potential therapeutic target. Here, CCN2 is linked to pulmonary hypertension.